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1123-110 Long-Term Prognosis of Patients With Myocardial 
Infarction and Normal Coronary Angiography: Impact of 
Inherited Coagulation Disorders 
Antoine Da Costa, Brigitte Tardy, Kamel Haouchette. Patrick Mismetti. Alexis Cerisler, 
Michel Lamaud, Denis Guyotat, Karl Isaaz, CHU NORD, Saint-Etienne, France 
Prevalence of inherited coagulation disorders including factor V Leiden is higher in pts 
with myocardial infarction (MI) and normal coronary angiography (NCA) than in pts with 
MI and coronary artery stenosis. Despite a good long-term prognosis of pts with NCA, 
the prognosis of those with inherited coagulation disorders is unknown. Objectives. The 
purpose of this study was to compare the clinical thrombosis Outcome of pts with (Gpl) or 
without (Gpll) an inherited coagulation disorders who suffered from an acute Ml with 
NCA. Methods. From September 1994 to November 2000, 82 consecutive pts (mean 
age 49k15 years; 29 females) with MI but NCA were recruited. Results. Twelve pts 
(15%) had an inherited coagulation disorder: APC resistance in 8 pts, factor XII defi- 
ciency in 3 pts and protem C deficiency in 1 pt. Gpl and Gpll were statistically similar 
regarding age (45*11 vs 50+16 years-old), gender (33 vs 36% female), tobacco (50 vs 
53%). diabetes mellltus (8 vs IO%), hypertension (25 vs 17%), obesity (8.3 vs 14%), cor- 
onary heart disease family history (33 vs 19%), hypercholesterolemia (50 vs 21%; 
pz.08). and left ventricular ejection fraction (58i13 vs 61+13%). Prevalence of coronary 
spasm did not differ significantly (8.3% vs 17%) between the two gps. All patients were 
Initially treated with antlplatelet agents with the exception of one (8%) in Gpl and 6 (9%) 
I” Gall who were under oral anticoaaulant therapv (ns). The mean follow-up was 57226 
(range from 2-91 months). Four patients were loit if &low-up. 0% in Gpl and 5.7% in 
Gnll ins~. Durina the outcome. 12178 115.4%) thrombotic events occurred. includina 
Y~n&~hrombosis or pulmonary embolism (I;12 vs l/66). reinfarction (2112 vs 4/66j, 
and stroke (202 vs 2/66), two events in one patient (Gpl). Kaplan-Meler event-free sur- 
vival, with combined end-point defined as venr~us thrombo-embolic event, reinfarction, or 
stroke dlffered between the two groups: 402 (33.3%) in Gpl and 7/66 (10.6%) in Gp II (p 
c.02). Conclusions. Patients with MI. NCA and congenital coagulation disorder present a 
high risk of thombotlc recurrence under antlplatelet agent. This new finding supports the 
hypothesis that anticoagulation therapy should be recommended in this selected situa- 
tion. 
difference was found for C-reactive protein levels ( 44.08 +I- 6.9 vs 12.25 +/- 2.7 mgll, p= 
O.OPS).Conclusion:: 1. The comparison of infarct-size-matched patients with and wfthout 
VF during an AMI reveals a significantly higher inflammatory activity in patients with VF. 
2. The duration of repolarization but not the dispersion correlates positively with C-reac- 
tive protein levels in patients with complicating VF versus patients wIthout VF. 3. Inflam- 
matory activity may play a triggering role for the development of ventricular fibnllation in 
AMI. 
1123-113 Direct Physiological Evidence of Damage to Collaterals 
During Primary Coronary Angioplasty for Acute 
Myocardial Infarction 
Robv D. Rakhit ChrIstian Seiler, Kerstin Wustmann, Stephan Zbinden, Stephan 
Windecker, Bernhard Meler, Franz Eberli. Swiss Cardiovascular Center, Bern, 
Switzerland 
Background: Distal microembolisation of thrombotic debris during primary percutaneous 
coronary intervention(PCI) for acute myocardial Infarction (AMI) may result in microcircu- 
latory dysfunction. We tested the hypothesis that microembolisation during balloon 
angioplasty could result in damage to collaterals. 
Methods: we measured Doppler-derived collateral flow index (CFI) in 11 consecutive 
patients (age 64*1 I, 9 male, 2 female) who underwent successful primary PCI for AMI 
(LAD 6, RCA 5). All patients received abciximab.CFl was compared dunng 1st and 2nd 
balloon inflations. CK and troponin I measurements were obtained from femoral venous 
plasma. Area at risk was determined off-line by coronary arteriography. 
Results: There was a significant reduction in mean CFI between 1st and 2nd balloon 
inflation (0.35*0.1 versus 0.22+0.1, p=O.Ol, 37% mean reduction). 24 hour CK and 
troponin I results were compared between patients with >30% reduction in CFI and those 
with ~30% reduction in CFI. CFI reduction z-30% was associated with higher CK and 
troponin levels at 24 hours independent of time to reperfusion or area at risk. The per- 
centage reduction in CFI between 1st and 2nd Inflation correlated positively with 24 hour 
troponin levels (r=0.6, p=O.O4). 
Conclusion: this study demonstrates an abrogation of collateral flow in response to 
sequential balloon inflations during primary PCI for AMI associated with a greater degree 
of myonecrosls. We suggest that this phenomenon is a result of damage to collaterals. 
CFI Reduction >30% CFI Reduction ~30% P 
1123-111 Interleukin-18 Levels Suggest Different Inflammatory 
Pathways in Unstable Angina 
Luiqi M. Biasucci, Matteo Santamaria. Dominick J. Angiolillo, Glovanna Di Glannuario, 
Glulia Aguzzi, Maria Elena Lombardi, Donatella Lomaglio. Giovanna LIUZZO, Attilio 
Maseri, Charles A. Dmarello. Filippo Crea. Catholic University, Rome, Italy 
Background. lnterleukin (IL)-18 is a cytokine that plays a central role in the inflammatory 
cascade, inducing IFN-gamma production by Thl lympochytes, acting ln sinergy with IL- 
12. IL-18 has been recently associated with increased risk of cardiac event. We aimed to 
lnvestlgate if IL-18 has a role in the acute phase response of unstable angina (UA) and if 
there IS a correlation between IL-18 and other inflammatory markers. Methods. We stud- 
ied 38 UA (Braunwald class IIIB) patients, 26 stable angina patients (SA) and 5 healthy 
controls (C). In all patients we measured plasma levels of IL-18, C-reactive protein (CRP) 
and IL-IRa, a reliable indicator of IL-I family cytokine production. UA patients were sub- 
grouped according to CRP levels in UAH (25 patients with CRP z-3 mg/L) and in UAL (13 
patients with CRP <3 mg/L). Results. IL-18 levels (ng/mL; median, range) were signifi- 
cantly higher in UAH and SA vs UAL and C (respectively: 0.098, 0.003-2.122; 0.178, 
0.003-0.904; 0.012. 0.003-0.78; 0.003, 0.003-0.03; p<O.Ol). CRP levels (mglL; median, 
range) were significantly higher in UAH vs UAL, SA and C (respectively: 9.8, 3.1-43.4; 
0.8, 0.8-2.9; 1.65,0.8-29.7; 1.2, 0.8-4.2; p<O.Ol). IL-1 Ra levels (pg/mL; median, range) 
were sigmflcantly higher in UAH vs UAL, SA and C (respectively: 3444, 200-12000; 973, 
200-9920; 1746, 200-12000; 325, 200-1984; p<O.Ol). A positive linear correlation was 
observed between plasma levels of IL-18 and IL-IRa (r=O.36. pcO.Ol), but not between 
CRP and IL-18. Correlatum between CRP and IL-I Ra levels was of borderline signlfi- 
cance (p&054). Conclusions. Our data confirm that IL-18 is associated wdh ischemic 
heart disease, but also indicate that different pathogenetic mechanisms may be involved 
in UA. In fact UA patients with low CRP also have low IL-18 and IL-IRa levels, suggest- 
Ing a different pathogenetlc component, possibly unrelated to acute Inflammatory 
response. 
1123-112 Comparison of Repolarization and Inflammatory 
Activity In Patients With and Without Ventricular 
Fibrillation During Acute Myocardial Infarction of a 
Similar Size (CK<lOOO U/I) 
Ayse Bilbal, Susanne Spehl, Constanze Echternach, Jijrgen Kuschyk, Flonan Streitner, 
S&fan Pfleger. Tim Sirselbeck, Karl K. Haase, Martin Borggrefe,Chnstian Wolpert 
University of Mannheim, Mannhelm, Germany 
Duration of repolarization and QT.dispersion during acute myocardial infarction (AMI) 
predict a risk for major cardiac events, if they do not normalize after catheter Intervention 
or thrombolysis. The aim of the present study was to assess the differences in QTc-inter- 
val and QT-dispersion during the acute myocardial infarction and assess the potential 
correlation between the QT-dispersion. QTc and factors as infarctton size, C-reactive 
protein serum level and serum potassium III patients with and without ventricular fibrilla- 
tion during AMI. Patients and Methods: In 43 patients (CK cl000 U/l) with (VF) and 77 
patients without ventncular fibrillation (Non-VF) dunng the acute phase of myocardial Inf- 
arction QTc, QT-dlsperslon. serum potassium, C-reactive protein and CK max were doc- 
umented and analysed. Results: While there was a similar distribution of gender, age and 
CK-level we found a significantly higher baseline heart rate in patients with VF (87+/- 
2,85 bpm) vs Non-VF (71.11 +I- 2.06 bpm). No significant differences were found in 
QTmax (0.43+/-0.09 seconds(s). vs 0.44 +/- 0.08 s) , QTcmax. (0.5 +/- 0.06 s vs 0.5 +/- 
0.05 s) and !n serum potassium-levels (4.02+/- 0.6 vs 4.29 +/- 0.6 mmol/l). A significant 
n 5 6 
CK (U/L) 
Troponin I (u/L) 
Reperfus~on (hrs) 
Area at risk (“I&.) 
1214+604 52lk273 0.03 
205+107 86*50 0.04 
8zt5 II*8 NS 
25*2 24+9 NS 
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1124-89 Pharmacodynamics of Eptifibatide and Abciximab in 
Patients With Non-ST Segment Elevation Acute 
Coronary Syndromes (TAM2) 
Jorge Saucedo, Luis Garza, Zakaria Matin, Henry K. Lui, Guerraumberto J. Guerra, 
Jeffrey W. Young, Mary V. Jacoski, Lisa K. Jennlnaa University of Tennessee Health 
Science Center, Memphis, TN 
Background: The importance of the relationship between clinical outcome and degree 
of platelet aggregation inhibitum (PAI) induced by GPllb-llla inhibitors used in large trials 
in patients with non-ST segment elevation (NSTE) acute coronary syndromes (ACS) is 
increasingly appreciated. In the PURSUIT trial. eptifibatide treatment targeted to achieve 
90% platelet aggregation inhibition was associated with clmical benefit at 30 days and 6 
months. The GUSTO IV ACS trial, however, failed to show any statistically significant 
benefit of abciximab treatment on 30 day outcomes. This difference might be linked to 
variability of antlplatelet effects of these agents. Methods: We conducted a prospective 
study in 40 patients with NSTE ACS prior to catheterization or coronary intervention at 3 
centers using the PURSUIT dose of eptlfibatide (180/0.2) and the GUSTO IV dose of 
abciximab (0.25/0.125). Blood samples were collected at baseline. and during the infu- 
sion at 10 min, 1 hr, 6 hr. 8 hr. 12 hr, 18 hr, and 24 hr. Measurements of ex viva light 
transmission aggregometry (LTA) were performed using PPACK anticoagulant and 20 
pM ADP agonist. Receptor Occupancy (RO) using the D3 monczlonal antibody assay 
was also determined in a subset of patients. Results: Eptifibatide achieves higher PAI 
during the entire infusion period than abciximab (p < 0.01). At IO min, average PAI with 
eptifibatlde and abciximab was 88% and 80% respectively, 95% and 79% at 6 hours, 
and 97% and 79% at 24 hours. There was also mcxe vanability in individual patient 
response to abclxlmab. Although average RO for eptiflbatide was similar to that of abcix- 
imab at IO min, average RO in the eptifibatlde treatment arm was higher at all subse- 
